T-cell-immunity During Standard Radiotherapy in Localised Prostate Cancer
August 15, 2013 updated by: Franziska Eckert, University Hospital Tuebingen
Changes of T-cell-immune-status During Curative Radiotherapy in Prostate Cancer
Immunological effects of radiotherapy have been described before, but not evaluated in a time-dependant manner.
In order to identify a possible time frame for combination therapies, white blood cells are isolated of samples taken at different time points before during and after standard radiotherapy in patients with localised prostate cancer. The overall activity of the T-cell-system as well as tumor-specific T-cell-response are evaluated.
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
22
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tuebingen, Germany, D-72076
- Department of Radiation Oncology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 90 years (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Sampling Method
Non-Probability Sample
Study Population
Patients undergoing standard radiotherapy for localised prostate cancer at the University Hospital of Tuebingen
Description
Inclusion Criteria:
- Localised prostate cancer (node negative)
- definitive radiotherapy
- informed consent
Exclusion Criteria:
- medication including steroids or immunosuppressants
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
T-cell-immunity in time-course
Time Frame: During and 3-6 months after radiotherapy
|
During and 3-6 months after radiotherapy
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Cihan Gani, M.D., University Hospital Tuebingen
- Study Director: Franziska Eckert, MD, University Hospital Tuebingen
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Widenmeyer M, Shebzukhov Y, Haen SP, Schmidt D, Clasen S, Boss A, Kuprash DV, Nedospasov SA, Stenzl A, Aebert H, Wernet D, Stevanovic S, Pereira PL, Rammensee HG, Gouttefangeas C. Analysis of tumor antigen-specific T cells and antibodies in cancer patients treated with radiofrequency ablation. Int J Cancer. 2011 Jun 1;128(11):2653-62. doi: 10.1002/ijc.25601. Epub 2010 Oct 8.
- Hoffmann E, Paulsen F, Schaedle P, Zips D, Gani C, Rammensee HG, Gouttefangeas C, Eckert F. Radiotherapy planning parameters correlate with changes in the peripheral immune status of patients undergoing curative radiotherapy for localized prostate cancer. Cancer Immunol Immunother. 2022 Mar;71(3):541-552. doi: 10.1007/s00262-021-03002-6. Epub 2021 Jul 16.
- Eckert F, Schaedle P, Zips D, Schmid-Horch B, Rammensee HG, Gani C, Gouttefangeas C. Impact of curative radiotherapy on the immune status of patients with localized prostate cancer. Oncoimmunology. 2018 Aug 27;7(11):e1496881. doi: 10.1080/2162402X.2018.1496881. eCollection 2018.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2011
Study Registration Dates
First Submitted
June 16, 2011
First Submitted That Met QC Criteria
June 16, 2011
First Posted (ESTIMATE)
June 20, 2011
Study Record Updates
Last Update Posted (ESTIMATE)
August 16, 2013
Last Update Submitted That Met QC Criteria
August 15, 2013
Last Verified
August 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- UKT_RO_01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.